Impact of Diabetes Mellitus on Early and Midterm Outcomes After Transcatheter Aortic Valve Implantation (from a Multicenter Registry)
详细信息 查看全文
- 作者：Federico Conrotto ; Fabrizio D'Ascenzo ; Francesca Giordana ; Stefano Salizzoni ; Corrado Tamburino ; Giuseppe Tarantini ; Patrizia Presbitero ; Marco Barbanti ; Valeria Gasparetto ; Marco Mennuni ; Massimo Napodano ; Marco L. Rossi ; Michele La Torre ; Gaetana Ferraro ; Pierluigi Omed猫 ; Paolo Scacciatella ; Walter Grosso Marra ; Chiara Colaci ; Giuseppe Biondi-Zoccai ; Claudio Moretti ; Maurizio D'Amico ; et al.
- 刊名：The American Journal of Cardiology
- 出版年：1 February, 2014
- 年：2014
- 卷：113
- 期：3
- 页码：529-534
- 全文大小：459 K
文摘
Several clinical and procedural factors have been identified as predictors of early and midterm events after transcatheter aortic valve implantation (TAVI), but incidence and prognostic impact of diabetes mellitus (DM), especially insulin treated, on short- and midterm outcomes remain to be defined. All consecutive patients who underwent TAVI at our institutions were enrolled and stratified according to DM status. All-cause mortality at 30 days or in hospital and at follow-up was the primary end point, whereas periprocedural complications, rates of myocardial infarction, stroke, and reintervention at follow-up were the secondary ones. All end points were adjudicated according to the Valve Academic Research Consortium definitions. In all, 511 patients were enrolled: 361 without DM, 78 with orally treated DM, and 72 with insulin-treated DM. Orally treated DM patients were more frequently women, whereas insulin-treated DM patients were younger. Thirty-day Valve Academic Research Consortium mortality was not significantly higher in patients with orally treated DM and insulin-treated DM compared with patients without diabetes (6.4%, 9.7%, and 4.7%, p聽= 0.09). Bleedings, vascular complications, postprocedural acute kidney injury, and periprocedural strokes were not significantly different in the 3 groups. At midterm follow-up (median 400聽days), patients with insulin-treated DM had a significantly higher mortality rate (33.3% vs 18.6%, p聽= 0.01) and higher myocardial infarction incidence (8.3% vs 1.4%, p聽= 0.002) if compared with patients without diabetes. Strokes and reinterventions at follow-up were similar in the 3 groups. After multivariable adjustment, insulin-treated DM was independently correlated with death (hazard ratio 2, 95% confidence interval 1.3 to 3.3) and myocardial infarction (hazard ratio 3.73, 95% confidence interval 1.1 to 13). In conclusion, DM does not significantly affect rates of complications in patients who underwent TAVI. Insulin-treated DM, but not orally treated DM, is independently associated with death and myocardial infarction at midterm follow-up and should be included into future TAVI-dedicated scores.